Immunic, a clinical-stage biopharmaceutical company, is developing a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its most promising development program, IMU-838, is currently in Phase 3 clinical trials for the treatment of multiple sclerosis, including relapsing multiple sclerosis, as well as other chronic inflammatory and autoimmune diseases, potentially including COVID-19. The company is also working on IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, and IMU-856, which aims to restore intestinal barrier function in patients suffering from maladies like celiac disease, inflammatory bowel disease, and irritable bowel syndrome with diarrhea. Immunic, Inc. is headquartered in the bustling metropolis of New York, NY.
Immunic's ticker is IMUX
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 11-50 employees working at Immunic
It is imux.com
Immunic is in the Healthcare sector
Immunic is in the Biotechnology industry
The following five companies are Immunic's industry peers: